LU92200I2 - Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables - Google Patents

Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables

Info

Publication number
LU92200I2
LU92200I2 LU92200C LU92200C LU92200I2 LU 92200 I2 LU92200 I2 LU 92200I2 LU 92200 C LU92200 C LU 92200C LU 92200 C LU92200 C LU 92200C LU 92200 I2 LU92200 I2 LU 92200I2
Authority
LU
Luxembourg
Prior art keywords
disorders
constipation
conditions
dyspepsia
linaclotide
Prior art date
Application number
LU92200C
Other languages
English (en)
Other versions
LU92200I1 (fr
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92200(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of LU92200I1 publication Critical patent/LU92200I1/fr
Publication of LU92200I2 publication Critical patent/LU92200I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
LU92200C 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables LU92200I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
PCT/US2004/002390 WO2004069165A2 (fr) 2003-01-28 2004-01-28 Procedes et compositions pour le traitement de troubles gastro-intestinaux

Publications (2)

Publication Number Publication Date
LU92200I1 LU92200I1 (fr) 2020-06-02
LU92200I2 true LU92200I2 (fr) 2024-03-21

Family

ID=32854294

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92201C LU92201I2 (fr) 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables
LU92200C LU92200I2 (fr) 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92201C LU92201I2 (fr) 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables

Country Status (28)

Country Link
US (3) US20040266989A1 (fr)
EP (3) EP1594517B1 (fr)
JP (3) JP4584911B2 (fr)
KR (2) KR101227626B1 (fr)
CN (2) CN100589839C (fr)
AT (2) ATE365174T1 (fr)
AU (2) AU2004210161B2 (fr)
BE (1) BE2013C032I2 (fr)
BR (2) BR122018074353B8 (fr)
CA (1) CA2514507C (fr)
CY (5) CY1110905T1 (fr)
DE (2) DE602004007105T2 (fr)
DK (3) DK2246360T3 (fr)
ES (3) ES2387848T3 (fr)
FR (2) FR13C0029I2 (fr)
HU (1) HUS1300022I1 (fr)
IL (2) IL169863A (fr)
LT (1) LTC1594517I2 (fr)
LU (2) LU92201I2 (fr)
MX (1) MXPA05008097A (fr)
NL (1) NL300593I2 (fr)
NO (3) NO334112B1 (fr)
NZ (2) NZ570134A (fr)
PT (3) PT1911763E (fr)
RU (2) RU2543350C2 (fr)
SG (2) SG192300A1 (fr)
SI (3) SI1594517T1 (fr)
WO (1) WO2004069165A2 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233040D1 (de) 2001-03-29 2009-09-03 Synergy Pharmaceuticals Inc Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR101227626B1 (ko) * 2003-01-28 2013-02-01 아이언우드 파마슈티컬스, 인코포레이티드 위장병 치료 방법 및 위장병 치료용 조성물
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US20050266028A1 (en) * 2004-05-25 2005-12-01 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
WO2006046746A1 (fr) * 2004-10-26 2006-05-04 Ajinomoto Co., Inc. Agent préventif/thérapeutique pour des douleurs viscérales
US20090253634A1 (en) * 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
PT1937262T (pt) 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
WO2007101161A2 (fr) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Méthodes et compositions servant au traitement de troubles gastro-intestinaux
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
MX2009011898A (es) * 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
ES2559840T3 (es) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010005515A2 (fr) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Procédés d’expression de protéines
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
MX385591B (es) * 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
EP2365821A4 (fr) 2008-11-19 2013-09-04 Ironwood Pharmaceuticals Inc Forme cristalline de la linaclotide
EP2373296B1 (fr) * 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
CN102482326A (zh) * 2009-04-10 2012-05-30 科登制药科罗拉多公司 分离治疗用肽的方法
WO2011017502A2 (fr) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprenant du linaclotide
RU2012109415A (ru) * 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
US8507447B2 (en) 2009-11-09 2013-08-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
RU2012128509A (ru) 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
CN102869677B (zh) 2010-02-17 2015-07-08 硬木药品公司 胃肠病症的治疗
WO2011145062A1 (fr) 2010-05-21 2011-11-24 Link Research & Grants Corporation Traitement des acouphènes et de dysfonctions auditives apparentées
US8748575B2 (en) * 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides
CA2808091C (fr) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Formulations stables de linaclotide
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012037380A2 (fr) 2010-09-15 2012-03-22 Synergy Pharmaceuticals Inc. Préparations d'agonistes du guanylate cyclase-c et méthodes d'utilisation
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CA2835624A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z (ro) * 2011-07-07 2012-09-30 Elvira Andon Metoda de tratament al colitei ulceroase nespecifice acute
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
WO2014118180A1 (fr) 2013-01-30 2014-08-07 Sandoz Ag Forme cristalline de linaclotide
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP3492106B1 (fr) 2013-08-09 2021-02-17 Ardelyx, Inc. Composés et procédés d'inhibition du transport de phosphate
WO2016178979A1 (fr) * 2015-05-01 2016-11-10 Ironwood Pharmaceuticals, Inc. Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux
US20190071504A1 (en) * 2016-03-15 2019-03-07 The Regents Of The University Of California Methods And Compositions For Treating And Preventing Disease Associated With Alpha 8 Beta 1 Integrin
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
CN113260407B (zh) * 2018-10-23 2023-11-14 艾比科生物医学公司 输送装置
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
EP3972599B1 (fr) 2019-05-21 2025-10-22 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
EP4469468A1 (fr) 2022-01-28 2024-12-04 Fresenius Kabi iPSUM S.r.l. Procédé de préparation de linaclotide
WO2025207484A1 (fr) * 2024-03-25 2025-10-02 Merveille.Ai Utilisation d'aprépitant et d'un dipeptide cyclique pour le contrôle du poids

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32684A (en) * 1861-07-02 Stump-extkactob
US258687A (en) * 1882-05-30 Grain-binder
US266989A (en) * 1882-11-07 Automatic fire
US232013A (en) * 1880-09-07 Henry h
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US73628A (en) * 1868-01-21 mitchell
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (fr) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (fr) 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) * 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
SG50624A1 (en) 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0678018B1 (fr) 1993-01-06 2003-04-09 Kinerton Limited Conjugues moleculaires ioniques de polyesters biodegradables et de polypeptides biologiquement actifs
US5395490A (en) 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
ATE259648T1 (de) * 1993-10-26 2004-03-15 Univ Jefferson Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DK0835126T3 (da) 1995-06-27 2003-07-14 Elan Pharm Inc Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
ATE289994T1 (de) 1995-11-24 2005-03-15 Glaxosmithkline Spa Chinolin-derivate
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
EP0895517B1 (fr) 1996-04-23 2004-11-17 Ipsen Manufacturing Ireland Limited Polymeres polylactiques acides
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DK0975347T3 (da) 1997-02-28 2008-06-16 Nycomed Gmbh Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
ES2222613T3 (es) 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
ES2315753T3 (es) 1999-06-23 2009-04-01 Institut Pasteur Composiciones para el tratamiento de problemas de relaciones interpersonales y trastornos del comportamiento.
DE60027334T2 (de) 1999-08-18 2007-03-29 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
EP1220872A1 (fr) 1999-10-06 2002-07-10 Pharmacia Corporation Uroguanyline, anticancereux intestinal
WO2001032180A2 (fr) 1999-11-01 2001-05-10 Rodeva Limited Composition destinee au traitement de la constipation et du syndrome du colon irritable
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001064212A1 (fr) 2000-03-01 2001-09-07 University College London Modulateurs de l'absorption d'endocannabinoide et des recepteurs de vallinoide
PT1216707E (pt) 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
DE60233040D1 (de) * 2001-03-29 2009-09-03 Synergy Pharmaceuticals Inc Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
WO2002079235A2 (fr) 2001-03-30 2002-10-10 University Of Copenhagen Compositions et procedes de modulation de l'activite du recepteur signalant la guanylyl cylclase et de traitement de la maladie de meniere
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
DE10292434D2 (de) * 2001-06-05 2004-07-29 Yueksel Savas Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (fr) 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
US20040121961A1 (en) * 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
EP1531846A4 (fr) 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugues de ligand, adaptateur et agent cytotoxique, compositions associees et procedes d'utilisation relatifs
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
CN101310723A (zh) 2002-05-17 2008-11-26 迪欧加药品公司 有效的选择性阿片受体调制剂化合物的用途
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR101227626B1 (ko) * 2003-01-28 2013-02-01 아이언우드 파마슈티컬스, 인코포레이티드 위장병 치료 방법 및 위장병 치료용 조성물
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
WO2004071436A2 (fr) 2003-02-10 2004-08-26 Thomas Jefferson University Utilisation de ligands gcc
US20090253634A1 (en) 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders

Also Published As

Publication number Publication date
NO20053864D0 (no) 2005-08-18
IL169863A (en) 2012-10-31
BRPI0407071B8 (pt) 2021-05-25
EP1911763A2 (fr) 2008-04-16
DK1594517T3 (da) 2007-10-29
DE602004007105D1 (de) 2007-08-02
EP1594517A2 (fr) 2005-11-16
NO20053864L (no) 2005-10-26
EP2246360A1 (fr) 2010-11-03
CY1111058T1 (el) 2015-06-11
DK2246360T3 (da) 2012-08-13
ATE365174T1 (de) 2007-07-15
NL300593I1 (nl) 2015-10-21
RU2763796C2 (ru) 2022-01-11
JP5563384B2 (ja) 2014-07-30
JP2013116910A (ja) 2013-06-13
NO2014013I2 (no) 2014-05-21
KR20050106404A (ko) 2005-11-09
SI1594517T1 (sl) 2007-10-31
BR122018074353B8 (pt) 2023-05-02
NO20130460L (no) 2005-10-26
AU2004210161A1 (en) 2004-08-19
RU2005127058A (ru) 2006-03-10
SG168407A1 (en) 2011-02-28
DE602004007105T2 (de) 2008-02-28
CY1110905T1 (el) 2015-06-10
SI1911763T1 (sl) 2010-11-30
BE2013C032I2 (fr) 2023-08-22
WO2004069165A3 (fr) 2005-03-17
NZ541595A (en) 2008-08-29
FR13C0029I2 (fr) 2024-04-19
ES2350123T3 (es) 2011-01-18
SI2246360T1 (sl) 2012-10-30
ATE477268T1 (de) 2010-08-15
CA2514507A1 (fr) 2004-08-19
US7704947B2 (en) 2010-04-27
RU2008147983A (ru) 2010-06-10
FR13C0030I1 (fr) 2013-07-05
JP2010222377A (ja) 2010-10-07
RU2014153593A (ru) 2016-07-20
CN100589839C (zh) 2010-02-17
EP1594517B1 (fr) 2007-06-20
KR20110114682A (ko) 2011-10-19
LU92201I2 (fr) 2013-11-22
BR122018074353B1 (pt) 2019-07-16
KR101227626B1 (ko) 2013-02-01
PT1594517E (pt) 2007-07-20
KR101227627B1 (ko) 2013-01-31
EP1911763B1 (fr) 2010-08-11
CN101787073B (zh) 2013-12-25
HK1078768A1 (en) 2006-03-24
CY2013022I1 (el) 2020-05-29
RU2014153593A3 (fr) 2018-08-06
ES2387848T3 (es) 2012-10-02
NO334112B1 (no) 2013-12-09
CA2514507C (fr) 2012-03-20
RU2543350C2 (ru) 2015-02-27
EP1911763A3 (fr) 2008-06-25
SG192300A1 (en) 2013-08-30
CN101787073A (zh) 2010-07-28
JP4584911B2 (ja) 2010-11-24
MXPA05008097A (es) 2006-02-08
LTC1594517I2 (lt) 2020-03-10
NO336768B1 (no) 2015-11-02
PT2246360E (pt) 2012-08-31
AU2009235993A1 (en) 2009-11-26
CY2013021I1 (el) 2020-05-29
EP2246360B1 (fr) 2012-06-27
JP2006516631A (ja) 2006-07-06
RU2353383C2 (ru) 2009-04-27
WO2004069165A2 (fr) 2004-08-19
DE602004028678D1 (de) 2010-09-23
US20110124583A1 (en) 2011-05-26
LU92200I1 (fr) 2020-06-02
US20090005534A1 (en) 2009-01-01
CY1113217T1 (el) 2016-04-13
CY2013021I2 (el) 2025-07-04
NL300593I2 (nl) 2020-04-15
NO2014013I1 (no) 2014-06-02
PT1911763E (pt) 2010-11-18
HUS1300022I1 (hu) 2019-11-28
CN1795007A (zh) 2006-06-28
BRPI0407071B1 (pt) 2019-02-12
IL221380A0 (en) 2012-09-24
US20040266989A1 (en) 2004-12-30
BRPI0407071A (pt) 2006-01-24
NZ570134A (en) 2010-02-26
JP5748791B2 (ja) 2015-07-15
DK1911763T3 (da) 2010-11-15
EP1594517A4 (fr) 2006-03-29
FR13C0029I1 (fr) 2013-07-05
AU2009235993B2 (en) 2013-07-04
AU2004210161B2 (en) 2009-11-26
ES2285417T3 (es) 2007-11-16
US8080526B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
LU92201I2 (fr) Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables
SG153824A1 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A3 (fr) Compositions et methodes de traitement de troubles gastro-intestinaux
WO2005016244A3 (fr) Methodes et compositions pour le traitement de troubles gastro-intestinaux
WO2006086653A3 (fr) Procedes et compositions pour le traitement de troubles gastro-intestinaux
WO2007101158A3 (fr) Méthodes et compositions servant au traitement de troubles gastro-intestinaux
WO2008002971A3 (fr) Procédés et compositions destinés au traitement de troubles gastro-intestinaux
MX386452B (es) Composición farmacéutica para usarse en el tratamiento de trastornos gastrointestinales.
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
WO2005074575A3 (fr) Procedes et compositions pour traiter des troubles gastro-intestinaux
WO2007062168A3 (fr) Procede et compositions pour le traitement de desordres gastrointestinaux
WO2006102069A3 (fr) Methodes et compositions pour le traitement de l'hypertension et de troubles gastro-intestinaux